Navigation Links
SNM's clinical trials network gains added support from industry leader
Date:5/13/2009

Reston, Va.The SNM Clinical Trials Network, an initiative designed to address the need for streamlined drug discovery through the integration of imaging biomarkers into multi-center clinical trials, recently added Genentech, Inc. as a supporter.

SNM, the world's largest medical and scientific society for molecular imaging professionals, inaugurated the Clinical Trials Network in late 2008 to facilitate more cost-effective drug development through the integration and standardization of imaging biomarkers into Phase 1, 2, 3 and 4 therapeutic clinical trials. As part of this initiative, the society continues to bring together pharmaceutical developers, the imaging community, biomarker manufacturers and regulatory agencies to address critical needs for incorporating imaging biomarkers into multi-center trials. A formal introduction to the Clinical Trials Network was provided at a two-day workshop in Clearwater Beach, Fla. in February 2009 and additional educational sessions about the network are planned for June during SNM's 56th Annual Meeting in Toronto, Canada.

"We are gratified to have Genentecha pioneer in the field of developing targeted therapeuticsjoin us in this important endeavor, which we hope will broaden the scope and effectiveness of today's medical practice and lead to improved patient care in the near future," said Peter S. Conti, M.D., Ph.D., co-chair of the SNM Clinical Trials Network and professor of radiology, pharmacy and biomedical engineering at the University of Southern California. "We are pleased that such an innovative corporate leader supports our mission of advancing molecular imaging and therapy."

The use of imaging in clinical trials can help pharmaceutical developers determine earlier in the development process whether a new product is clinically promising by allowing physicians to see and assess whether it is working as intended for a patient, explained Dr. Conti.

"Molecular imaging is an essential component of such studies since it accelerates the development of promising compounds and eliminates those without apparent patient benefit earlier in the development cycle," he added. "We hope that Genentech's collaboration with SNM will help improve patient treatment worldwide."


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related biology news :

1. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
2. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
3. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
4. Cleveland Clinic leading clinical program to improve early-stage lung cancer detection
5. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
6. Study of African traditional medicine will begin world-first clinical trial
7. New clinical data shows chromium picolinate improves cognitive function
8. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
9. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
10. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
11. NHLBI issues first US von Willebrand Disease clinical practice guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 4, 2017  GCE Solutions, a global clinical research organization (CRO), ... anonymization solution on October 4, 2017. Shadow is designed to assist ... with policy 0070 of the European Medicines Agency (EMA) in meeting ... ... ...
(Date:6/30/2017)... June 30, 2017 Today, American Trucking ... supplier of face and eye tracking software, became ... provider program. "Artificial intelligence and ... to monitor a driver,s attentiveness levels while on ... able to detect fatigue and prevent potential accidents, ...
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology: